Podium to Practice: EHA 2025 – Lymphoma: UK FLair
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
S155 – IBRUTINIB PLUS VENETOCLAX WITH MRD-GUIDED DURATION OF TREATMENT IS SUPERIOR TO BOTH CONTINUOUS IBRUTINIB MONOTHERAPY AND FCR FOR PREVIOUSLY UNTREATED CLL: REPORT OF THE PHASE III UK FLAIR STUDY
This program has been made possible through unrestricted support from Eli Lilly, Merck & Roche.
Studies/trials discussed:
S155 – IBRUTINIB PLUS VENETOCLAX WITH MRD-GUIDED DURATION OF TREATMENT IS SUPERIOR TO BOTH CONTINUOUS IBRUTINIB MONOTHERAPY AND FCR FOR PREVIOUSLY UNTREATED CLL: REPORT OF THE PHASE III UK FLAIR STUDY
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.